You are invited to the OTS meeting that will be held on Friday, October 7, 2022.  We are excited to announce that our speaker for this meeting will be Dr. John Friedewald, a Professor of Medicine and the Medical Director of the kidney and pancreas transplant program at Northwestern Memorial Hospital.  

Dr. Friedewald is the lead investigator for a clinical trial for a new therapy developed by the biotech company CSL Behring for kidney transplant recipients.   CSL Behring has a clinical trial for Chronic antibody Rejection (CAMR) in kidney transplant recipients.  CAMR is a serious and rare condition and one of the leading causes of kidney transplant failure.   This clinical trial will evaluate the safety and efficacy of a new therapy to prevent allograft loss due to CAMR.  Dr. Friedewald will explain about Chronic antibody rejection and the importance of this clinical trial. 

This meeting will be held on Zoom, and the login info is listed below.

Topic: OTS Educational Meeting

Time: Oct 7, 2022 07:00 PM Central Time (US and Canada)

Join Zoom Meeting

https://us06web.zoom.us/j/81423606385?pwd=NEF6UEtVS3dsL2FSZFp6b2lSL1drUT09

Please join us for this important OTS meeting on Friday, Oct. 7.